[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR121207A1 - Composición de liberación controlada - Google Patents

Composición de liberación controlada

Info

Publication number
AR121207A1
AR121207A1 ARP210100224A ARP210100224A AR121207A1 AR 121207 A1 AR121207 A1 AR 121207A1 AR P210100224 A ARP210100224 A AR P210100224A AR P210100224 A ARP210100224 A AR P210100224A AR 121207 A1 AR121207 A1 AR 121207A1
Authority
AR
Argentina
Prior art keywords
water
release composition
controlled release
soluble polymer
hydrogel
Prior art date
Application number
ARP210100224A
Other languages
English (en)
Inventor
Shoji Furuta
Hiroki Wakamori
Naoto Hattori
Chihiro Ishida
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AR121207A1 publication Critical patent/AR121207A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una composición de liberación controlada caracterizada porque comprende (1) un polímero soluble en agua, en donde el polímero soluble en agua forma un hidrogel en agua y la resistencia del hidrogel es inferior a 10 N. Reivindicación 3: La composición de liberación controlada según la reivindicación 1, caracterizada porque (1) el polímero soluble en agua es al menos uno seleccionado del grupo de óxido de polietileno (PEO), un derivado de celulosa preferiblemente hipromelosa (HPMC), metilcelulosa, hidroxietilcelulosa, hidroxipropilcelulosa (HPC), hidroxietilmetilcelulosa, carboximetilcelulosa, carboximetilcelulosa sódica, alcohol polivinílico (PVA), ácido algínico, una sal de metal alcalino de ácido algínico, alginato de amonio, carragenina, goma xantana y goma arábiga. Reivindicación 7: La composición de liberación controlada de acuerdo con cualquiera de las reivindicaciones 5 ó 6, caracterizada porque (2) el aditivo soluble en agua es al menos uno seleccionado del grupo de polivinilpirrolidona (PVP) y azúcares preferiblemente alcohol de azúcar. Reivindicación 10: La composición de liberación controlada según la reivindicación 9, caracterizada porque (3) el ingrediente activo es selexipag.
ARP210100224A 2020-01-31 2021-01-29 Composición de liberación controlada AR121207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020014880 2020-01-31

Publications (1)

Publication Number Publication Date
AR121207A1 true AR121207A1 (es) 2022-04-27

Family

ID=77079418

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100224A AR121207A1 (es) 2020-01-31 2021-01-29 Composición de liberación controlada

Country Status (4)

Country Link
AR (1) AR121207A1 (es)
TW (1) TW202140010A (es)
UY (1) UY39054A (es)
WO (1) WO2021153716A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO112991B1 (ro) * 1992-09-18 1998-03-30 Yamanouchi Pharma Co Ltd Preparat tip hidrogel, cu eliberare sustinuta
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017042731A1 (en) * 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
EP3335699A1 (en) * 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
EP3711763A4 (en) * 2017-11-16 2021-08-18 Nippon Shinyaku Co., Ltd. CONTROLLED RELEASE FORMULATION
WO2020157730A1 (en) * 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
EP3705115B1 (en) * 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
WO2020255157A1 (en) * 2019-06-20 2020-12-24 Aizant Drug Research Solutions Private Limited Stable solid dosage form of selexipag and process for preparation thereof

Also Published As

Publication number Publication date
TW202140010A (zh) 2021-11-01
WO2021153716A1 (en) 2021-08-05
UY39054A (es) 2021-07-30

Similar Documents

Publication Publication Date Title
Colinet et al. New amphiphilic and pH-sensitive hydrogel for controlled release of a model poorly water-soluble drug
HRP20180965T1 (hr) Formulacija lijeka s produženim otpuštanjem
AR071420A1 (es) Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla
RU2018112239A (ru) Фармацевтическая композиция на основе трамадола для офтальмологического применения
JP2019142974A5 (es)
RU2014144727A (ru) Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия
CA2464578A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
WO2010070664A4 (en) Curcuminoids and its metabolites for the application in ocular diseases
JP2018021007A5 (es)
RU2019113770A (ru) Лиофилизированные фармацевтические композиции для вагинальной доставки
RU2012146100A (ru) Легко дозируемый твердый препарат
PH12020550009A1 (en) Pharmaceutical preparation and preparation method therefor
AR121207A1 (es) Composición de liberación controlada
WO2018056937A3 (en) Nanofibrous adhesion barrier
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
JP2019532109A5 (es)
JP2013521245A (ja) 耳の炎症の治療を目的とするフルオシノロンアセトニドの透明な水性溶液
RU2007137434A (ru) Таблетированный препарат с замедленным высвобождением для вертиго
JP2019104727A5 (es)
JP2019142979A5 (es)
FI3744316T3 (fi) Oftalminen farmaseuttinen koostumus, menetelmä sen valmistamiseksi ja sen käyttö
JP2011513393A5 (es)
HRP20150578T1 (hr) Metoda za stabilizaciju s-nitrozoglutationa i sastav pripremljen tom metodom
KR20190019058A (ko) 만성 상처의 괴사조직제거 방법
RU2012133568A (ru) Способы и композиции для нанесения моксифлоксацина в ухо

Legal Events

Date Code Title Description
FB Suspension of granting procedure